Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: https://peartherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/26/2022 | $5.00 | Neutral | B of A Securities |
| 1/20/2022 | $11.00 | Outperform | Credit Suisse |
| 1/3/2022 | $12.00 | Buy | BTIG Research |
| 12/29/2021 | $13.00 | Buy | Citigroup |
| 12/22/2021 | $16.00 | Buy | Chardan Capital |
| 12/16/2021 | Outperform | Cowen & Co. |
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit
B of A Securities initiated coverage of Pear Therapeutics with a rating of Neutral and set a new price target of $5.00
Credit Suisse initiated coverage of Pear Therapeutics with a rating of Outperform and set a new price target of $11.00
BTIG Research initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $12.00
Citigroup initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $13.00
Chardan Capital initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $16.00
Cowen & Co. initiated coverage of Pear Therapeutics with a rating of Outperform
SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)
SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)
SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)
SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)
SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)
SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)
Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su
Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value. The Company has engaged MTS Health Partners, L.P. to act as the Company's exclusive financial advisor to assist in evaluating potential alternatives. MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry. As part of its process, Pear is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston. Corey McCann, M.D., Ph.D., President and CEO, will represent the Company in an analyst-led fireside chat on Monday, March 6 at 9:10 a.m. Eastern Time. A live audio webcast can be accessed by clicking here and will be made available in the Investors section of Pear's website at www.peartherapeutics.com. A replay of the webcast will be available on Pear's website for up to 30 days following the live presentat
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference. BTIG hosted events are intended for prospective and existing BTIG clients only. To request a meeting with Pear management, please contact your BTIG representative to express interest. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the p
BrightView expands its initiative with reSET® and reSET-O® to patients across Kentucky, Ohio, Delaware, Massachusetts, and Virginia Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health, an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs. This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®. BrightView, an innovative and patient-focused leader in SUD and OUD tr
Pear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023 Florida Medicaid is covering reSET® and reSET-O® for the treatment of substance use disorder and opioid use disorder, respectively, giving Medicaid patients in Florida access to innovative FDA-authorized addiction treatments via their mobile devices Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET. Corey McCann, M.D., Ph.D., President and CEO, will participate in the Citi analyst-hosted fireside chat to discuss Pear's progress on market access. Citi hosted events are intended for prospective and existing Citi clients only. To listen to the live event, please contact your Citi representative with interest. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR,
The California Department of Health Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California's Contingency Management Program, to treat Medi-Cal members with stimulant use disorder DHCS intends to use the pilot as a basis for informing the design and implementation of a statewide contingency management benefit through the Drug Medi-Cal Organized Delivery System, pending budgetary and statutory authority The California Department of Health Care Services (DHCS) has selected Pear Therapeutics, Inc. (NASDAQ:PEAR), a leader in developing and commercializing software-based medicines, to support the implementat
25-NSE - Pear Therapeutics, Inc. (0001835567) (Subject)
8-K - Pear Therapeutics, Inc. (0001835567) (Filer)
8-K - Pear Therapeutics, Inc. (0001835567) (Filer)
10-K - Pear Therapeutics, Inc. (0001835567) (Filer)
8-K - Pear Therapeutics, Inc. (0001835567) (Filer)
8-K - Pear Therapeutics, Inc. (0001835567) (Filer)
S-8 - Pear Therapeutics, Inc. (0001835567) (Filer)
EFFECT - Pear Therapeutics, Inc. (0001835567) (Filer)
424B5 - Pear Therapeutics, Inc. (0001835567) (Filer)
424B3 - Pear Therapeutics, Inc. (0001835567) (Filer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
4 - Pear Therapeutics, Inc. (0001835567) (Issuer)
Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "
Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the
20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de
Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its second quarter 2022 financial results after the close of market on Thursday, August 11, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the
108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pear's first 12-month and 24-month real-world health economic data presented at ISPOR Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported financial results for its first quarter ended March 31, 2022. "Our momentum in 2021 continued into 2022 with strong revenue and prescription volume growth in the first quarter," said Corey
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, May 16, 2022. The company will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss its financial and business highlights. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 6975673. A live webcast will also be available in the Investors section of the company's website at www.
$4.2 million total revenue for the full year 2021 2021 highlights include Current Procedural Terminology (CPT) codes for prescribers, first state Medicaid coverage decision, two major PBM formulary additions, more than 30 organizations providing access, and 9-month HEOR data published Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today reported financial results for its fourth quarter and full year 2021 ended December 31, 2021. Fourth Quarter 2021 Financial Results Pear's total revenue for the fourth quarter of 2021 was $1.3 million, compared with $34 thousand for the fou
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 8586341. A live webcast will also be available in the Investors section of the company's website at www.peartherapeutics.com. A replay of the webcast will be available in the Investors
Pear Therapeutics announces the acquisition and license of two digital therapeutic assets designed to treat patients with a range of depression symptoms Pear is developing a prescription digital therapeutic (PDT) candidate that may be developed for use alone or in combination with pharmacotherapy to treat patients across a continuum of depression subtypes and severities Pear intends to incorporate both newly acquired and licensed assets into Pear's depression candidate, which will require clinical evaluation, and if promising, would then be evaluated in a potential pivotal clinical trial to support FDA submission Depression represents one of the largest areas of unmet medical need